What the CJC-1295 / Ipamorelin blend is
This product, usually searched as CJC 1295 Ipamorelin or CJC1295 Ipamorelin, is a co-lyophilised preparation of two peptides from the growth-hormone-releasing literature that are routinely studied together: CJC-1295 without DAC, the tetrasubstituted analogue of the first 29 residues of growth-hormone-releasing hormone, and ipamorelin, the pentapeptide ghrelin-receptor agonist developed at Novo Nordisk. The two are dissolved together in equal amounts, 5 mg of each or 10 mg of each, freeze-dried together in a single vial. The powder is a physical mixture at a fixed ratio, not a conjugate, and the peptides behave independently once dissolved.
CJC-1295 no DAC has an average molecular weight of approximately 3,368 g/mol and ipamorelin approximately 712 g/mol, so equal masses correspond to roughly five times as many moles of ipamorelin. Neither carries a lipid or a metal. The blend is listed in our blends class.
The published literature on the compound, with references, is collected in the monograph.
What you receive
Each vial contains the two peptides as a white lyophilised powder, sealed with a flip-off cap over a crimped stopper, in the net quantities stated on the label: 5 mg + 5 mg or 10 mg + 10 mg. There is no carrier, mannitol or other excipient unless the batch certificate says otherwise. The batch number is printed on the label and matches the certificate in our register. The limitation of a blend is the fixed ratio; a design that needs the two components varied independently should use the single-compound vials of each.
Reading the certificate for a blend batch
Identity by LC-MS is confirmed for each component separately. The laboratory looks for the expected mass of about 3,368 Da for CJC-1295 no DAC and about 712 Da for ipamorelin. Both must be present, and the CJC-1295 mass in particular must match the no-DAC value; a mass some 150 Da higher would indicate the DAC-linked form. Purity by reversed-phase HPLC shows two well-separated main peaks, and the reported purity is their combined area against all peaks; it should be above 98% for a well-made lot. Net content is reported for the vial as a whole and, where quantified, per component.
The impurities expected are deletion sequences and oxidation of the methionine in CJC-1295, both of which elute near its main peak. Our guide to reading a certificate of analysis includes a blend example, and HPLC and LC-MS explained describes the methods.
Storage and handling
Sealed vials should be kept refrigerated at 2 to 8 °C and protected from light; −20 °C is preferable for storage beyond a few months, and the lyophilised blend is stable for well over a year under those conditions. Allow the vial to reach room temperature before opening to avoid condensation. The powder dissolves readily in water or bacteriostatic water to give a clear solution containing both peptides. CJC-1295 contains a methionine and is the more oxidation-sensitive of the two, so solutions should be aliquoted and frozen rather than kept refrigerated for long; the storage and stability guide covers solvents, concentrations and freeze-thaw behaviour.